Researchers in cancer proteases, basic cancer researchers, oncologists, those working in the areas of bioinformatics, proteomics, cancer chemistry, drug development

Table of contents:

Section 1: The Degradome and its analysis

Chapter 1: Protease Genomics and the Cancer Degradome

Xose S. Puente, Gonzalo R Ordonez & Carlos López-Otín

Chapter 2: The CLIP-CHIP: A focused oligonucleotide microarray platform for transcriptone analysis for the complete human and murine cancer degradomes.

Rheinhild Kappelhoff, Claire H.Wilson, & Christopher M. Overall

Chapter 3: The Hu/Mu ProtIn chip: A custom dual-species Oligonucleotide Microarray for profiling degradome gene expression in tumours and their microenvironment

Donald R.Scwartz, Kamiar Moin, Ekkehard Weber & Bonnie F Sloane

Chapter 4: Quantitative Real-Time PCR analysis of degradome gene expression

Caroline J Pennington, Robert K. Nuttall, Clara Sampieri -Ramirez, , Matthew Wallard, Simon Pilgrim & Dylan R. Edwards

Chapter 5: Identification of protease substrates by mass spectrometry approaches.

Mari Enoksson,Wenhong Zhu & Guy Salvesen

Chapter 6: Identification of protease substrates by mass spectrometry approaches – 2.

Anna Prudova, Ulrich auf dem Keller & Christopher M. Overall

Chapter 7: Activity based imaging and biochemical profiling tools for analysis of the cancer degradome.

Vincent Dive, Margot Paulick, J.Oliver McIntyre, Lynn M. Matrisan & Matthew Bogyo.

Chapter 8: Images of cleavage

Kamiar Moin,Mansoureh Sameni, Christopher Jedeszko, Quanwen Li, Mary B. Olive, Raymond R. Mattingly & Bonnie F. Sloane

Section 2: Insights into Protease function

Chapter 9: Proteolytic pathways: Intersecting cascades in cancer development

Nesrine I. Affara & Lisa M, Coussens

Chapter 10: Physiological functions of plasminogen activation: Effects of gene deficiences in humans and mice

Thomas H. Bugge

Chapter 11: The plasminogen activation system in tissue remodelling and cancer invasion

Kasper Almholt, Anna Juncker-Jensen, Kirsty Anne Green, Helene Solberg, Leif Roge Lund & John Rømer

Chapter 12: The urokinase plasminogen activator receptor as a target for cancer therapy

Silvia D’Alessio & Francesco Blasi

Chapter 13: The endocytic collagen receptor uPARAP/Endo 180 in cancer invasion and tissue remodelling

Thore Hillig, Lars H. Engelholm & Niels Behrendt

Chapter 14: Physiological and pathological functions of type II transmembrane serine proteinases:Lessons from transgenic mouse models and human disease-associated mutations.

Karin List & Thomas Bugge

Chapter 15: Analysis of cysteine cathepsin knockout mice in cancer models

Thomas Reinheckel, Vasilena Gocheva, Christoph Peters & Johanna A. Joyce

Chapter 16: In vitro and in vivo models of angiogenesis to dissect MMP functions.

Sarah Berndt, Françoise Bruyère, Maud Jost & Agnès Noël

Chapter 17: The surface transplantation model to study the tumour-host interface

Maud Jost, Silvia Vosseler, Silvia Blacher, Norbert E. Fusenig, Margareta Mueller & Agnes Noel

Chapter 18: Unravelling the roles of proteases in cell migration in vitro and in vivo

Jelena Gavrilovic & Xanthe Scott

Chapter 19: New insights into MMP function in adipogenesis

Kumari L Andarawewal & Marie-Christine Riol

Chapter 20: TIMPs:Extracellular Modifiers in Cancer Development

Aditya Murty,William Cruz-Munoz & Rama Khokha

Section 3: The interface between Proteolysis and Cell Signalling

Chapter 21: Invadopodia: Interface for Invasion

Susette C Mueller, Vira V. Artym & Thomas Kelly

Chapter 22: uPAR and proteases in mobilization of hematopoietic stem cells

Pia Ragno & Francesco Blasi

Chapter 23: The urokinase receptor (uPAR) and integrins constitute a cell migration signalosome

Bernard Degryse

Chapter 24: Measuring uPAR dynamics in live cells

Moreno Zamai, Gabriele Malengo & Valeria R. Caiolfa

Chapter 25: Janus-faced effects of broad-spectrum and specific MMP inhibition on metastasis

Charlotte Kopitz & Achim Kruger

Chapter 26: Cytokine Substrates: MMP regulation of inflammatory signalling molecules

Jennifer H. Cox & Christopher M. Overall

Chapter 27: Matrix metalloproteinases as key regulators of tumour:bone interaction

Conor C. Lynch & Lynn M. Matrisan

Section 4: The degradome as source of cancer diagnostic and prognostic markers

Chapter 28: The plasminogen activation system as a source of prognostic markers in cancer

Ib Jarle Christensen, Helle Pappot & Gunilla Hoyer-Hansen

Chapter 29: Cysteine cathepsins and cystatins as cancer biomarkers

Tamara T. Lah, Natasa Obermaja, Maria Beatriz Duran Alonso & Janko Kos

Chapter 30: Novel degradome markers in breast cancer

Caroline J. Pennington, Simon Pilgrim, Paul N Span Fred C. Sweep & Dylan R. Edwards

Chapter 31: Meta-analysis of gene expression microarray data: Degradome genes in healthy and cancer tissues

Kristiina Iljin, Sami Kilpinen, Johanna Ivaska & Olli Kallioniemi

Chapter 32: Degradome gene polymorphisms

Ross Laxton & Shu Ye

Chapter 33: TIMP-1 as a prognostic marker in colorectal cancer

Camilla Frederiksen, Anne Fog Lomholt,Hans Jorgen Nielsen & Nils Brunner

Section 5: Novel therapeutic strategies

Chapter 34: Structure and inhibition of the urokinase-type plasminiogen activator receptor (uPAR)

Benedikte Jacobsen, Magnus Kjaergaard, Henrik Gardsvoll & Michael Ploug

Chapter 35: Engineered antagonists of uPA and PAI-1

M. Patrizia Stoppelli, Lisbeth M, Andersen, Giuseppina Votta & Peter A. Andreasen

Chapter 36: MMP inhibitor clinical trials – the past present and future

Barbara Fingleton

Chapter 37: Tailoring TIMPs for selective metalloproteinase inhibition

Hideaki Nagase & Gillian Murphy

Chapter 38: Third Generation MMP Inhibitors: Recent advances in the development of highly selective inhibitors

Athanasios Yiotakis & Vincent Dive

Chapter 39: Protease activated delivery and Imaging systems

Gregg Fields

Chapter 40: Development of tumour selective and endoprotease-activated anticancer therapeutics

Jason H. Gill & Paul M. Loadman

Chapter 41: Targeting Degradome genes via engineered Viral Vectors

Risto Ala-aho, Andrew H. Baker & Veli-Matti Kahari